Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 3/20 | 0.61 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.47 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29052130 | 0.85 | ERN1 (0.47) | ERN1MCL1POLBALDH1A1SMN1; SMN2 | |
| SCHEMBL9748117 | 0.82 | ERN1 (0.47) | ERN1MCL1CA1CA2CYP1A1 | |
| SCHEMBL3698426 | 0.81 | POLB (0.46) | ERN1MCL1CYP1A1CYP1B1POLB | |
| SCHEMBL28746938 | 0.81 | ERN1 (0.45) | ERN1MCL1POLBALDH1A1SMN1; SMN2 | |
| SCHEMBL11763980 | 0.81 | MAPT (0.58) | ERN1MCL1CYP1A1CYP1B1POLB | |
| SCHEMBL11239147 | 0.80 | ERN1 (0.73) | ERN1MCL1CA1CA2CYP1A1 | |
| SCHEMBL16055223 | 0.80 | ERN1 (0.48) | ERN1CYP1A1CYP1B1POLBKDM4E | |
| SCHEMBL5736579 | 0.80 | CA1 (0.51) | ERN1MCL1CA1CA2KDM4E | |
| SCHEMBL28458172 | 0.78 | MAPT (0.63) | ERN1MCL1CYP1A1POLBKDM4E | |
| SCHEMBL29729025 | 0.77 | CA1 (0.59) | ERN1MCL1CA1CA2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3344626-A1 | THERAPEUTIC COMPOUNDS FOR PAIN AND SYNTHESIS THEREOF | Janssen Pharmaceutica N.V. (BE) | 2018-07-11 | — | — | EP | claimed |
| WO-2017040767-A1 | THERAPEUTIC COMPOUNDS FOR PAIN AND SYNTHESIS THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2017-03-09 | — | — | WO | claimed |
| CN-106188011-A | The ultrasonic synthesis of the ring-type beta-lactam derivant of quaternary based on arylpyrazole skeleton and application | 中南民族大学 | 2016-12-07 | — | — | CN | claimed |
| CN-113801087-B | Benzo-six-membered ring derivatives as DPP-4 inhibitors and uses thereof | 山东百极地长制药有限公司 | 2024-08-30 | — | — | CN | disclosed |
| CN-113801088-B | Benzo six-membered ring derivative and application thereof | 山东百极地长制药有限公司 | 2024-04-26 | — | — | CN | disclosed |
| US-20230072421-A1 | TARGETED RADIOPHARMACEUTICALS FOR THE DIAGNOSIS AND TREATMENT OF PROSTATE CANCER | BAYER AS (NO) | 2023-03-09 | — | — | US | disclosed |
| EP-4003959-A1 | TARGETED RADIOPHARMACEUTICALS FOR THE DIAGNOSIS AND TREATMENT OF PROSTATE CANCER | Bayer AS (NO) | 2022-06-01 | — | — | EP | disclosed |
| CN-113801088-A | Benzo-six-membered ring derivative and application thereof | 山东百极地长制药有限公司 | 2021-12-17 | — | — | CN | disclosed |
| CN-113801087-A | Benzo-hexatomic ring derivative as DPP-4 inhibitor and application thereof | 山东百极地长制药有限公司 | 2021-12-17 | — | — | CN | disclosed |
| WO-2021013978-A1 | TARGETED RADIOPHARMACEUTICALS FOR THE DIAGNOSIS AND TREATMENT OF PROSTATE CANCER | BAYER AS (NO) | 2021-01-28 | — | — | WO | disclosed |
| EP-3109703-B1 | PHOTOSENSITIZATION CHEMICAL-AMPLIFICATION TYPE RESIST MATERIAL, AND METHOD FOR FORMING PATTERN USING SAME | TOKYO ELECTRON LTD (JP) | 2020-12-30 | — | — | EP | disclosed |
| US-4985442-A | ANTIINFLAMMATORY, LUNG DISEASES, PSORIASIS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-01-15 | — | — | US | disclosed |
| US-4985435-A | TREATMENT OF INFLAMMATION, OBSTRUCTIVE LUNG DISEASES AND PSORIASIS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-01-15 | — | — | US | disclosed |
| US-4906636-A | 2-Substituted-1-naphthols as 5-lipoxygenase inhibitors | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1990-03-06 | — | — | US | disclosed |
| US-4864021-A | ANTICARCINOGENIC AGENTS, ANTITUMOR AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1989-09-05 | — | — | US | disclosed |
| US-4833164-A | ANTIINFLAMMATORY AGENTS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-05-23 | — | — | US | disclosed |
| EP-0201071-A2 | 2-Substituted-1-naphthols as 5-lipoxygenase inhibitors | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1986-11-12 | — | — | EP | disclosed |
| EP-0180897-A2 | 5-Fluorouracil derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1986-05-14 | — | — | EP | disclosed |
| EP-0003074-A2 | Process for the preparation of 4-(6-methoxy-2-naphthyl)butan-2-one and 2-acetyl-3-(6-methoxy-2-naphthyl) propenoic acid esters | BEECHAM GROUP PLC (GB) | 1979-07-25 | — | — | EP | disclosed |
| US-4000275-A | BENZIMIDAZO(2,1-B) QUINAZOLIN-12(6H)ONES | ELI LILLY AND COMPANY (US) | 1976-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230072421-A1 | TARGETED RADIOPHARMACEUTICALS FOR THE DIAGNOSIS AND TREATMENT OF PROSTATE CANCER | KLK3, AR, SHBG | ERN1 2749/4885MCL1 4424/4885CA1 772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.